Educational guide
Bachem capabilities to address the new FDA guideline for synthetic peptides
Bachem capabilities to address the new FDA guideline for synthetic peptides “https://fast.wistia.com/embed/medias/z1rimheph3.jsonp” async> About the speakers Dr. Sergey Malashikhin Group Leader Generics Dr. Sergey Malashikhin is a Group Leader Generics – Busin
This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.
Bachem capabilities to address the new FDA guideline for synthetic peptides
“https://fast.wistia.com/embed/medias/z1rimheph3.jsonp” async>
About the speakers
Dr. Sergey Malashikhin
Group Leader Generics
Dr. Sergey Malashikhin is a Group Leader Generics – Business Development at Bachem Switzerland. In this position, together with his team he is responsible for customer projects with complex generic peptide APIs manufactured at Bachem as well as for early and development stage generics projects. Prior to joining Bachem he worked in a commercial role in a Swiss Life Science company and in R&D of a Japanese technology corporation. He earned his PhD in Organic Chemistry at the University of Zurich, Switzerland.
Dr. Martin Ostermaier
Product Manager for Research Chemicals and Specialties
Dr. Martin Ostermaier is Product Manager for Research Chemicals and Specialties at Bachem since September 2019. After his PhD at the ETH in Zürich he was Scientific Officer at the Paul Scherer Institute, where he was author of 10 scientific papers and inventor of 3 patents. At the same time, he was CEO, Co-Founder and Chairman of the Board of Directors at InterAx Biotech, where he transformed a business idea in the field of “Artificial Intelligence for Drug Discovery” into a commercially successful company with international customers.